Question

I am a breastfeeding mother and i want to know if it is safe to use 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)? Is 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl) safe for nursing mother and child? Does 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl) extracts into breast milk? Does 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl) has any long term or short term side effects on infants? Can 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl) influence milk supply or can 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl) decrease milk supply in lactating mothers?

Answer by DrLact: About 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl) usage in lactation

No information is available on the clinical use of 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl) during breastfeeding. Because 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl) and its metabolites are over 90% bound to plasma proteins, the amount in milk is likely to be low. However, the manufacturer recommends that breastfeeding be discontinued during 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl) therapy and for 3 weeks after the final dose.

Alternate Drugs

Trastuzumab(Unsafe)
Docetaxel(Dangerous)
Hydroxyurea(Low Risk)
Etoposide(Dangerous)
Dactinomycin(Dangerous)
Doxorubicin(Dangerous)
Nivolumab(Unsafe)
Ipilimumab(Unsafe)
Cyclophosphamide(Dangerous)
Vinblastine(Dangerous)
Imatinib(Unsafe)
Cladribine(Dangerous)
Gemcitabine(Dangerous)
Cetuximab(Unsafe)
Cisplatin(Unsafe)
Bleomycin(Dangerous)
Carboplatin(Dangerous)
Busulfan(Dangerous)
Vinorelbine(Dangerous)
Paclitaxel(Dangerous)
Dacarbazine(Dangerous)
Fluorouracil(Dangerous)
Letrozole(Dangerous)
Alemtuzumab(Low Risk)
Exemestane(Dangerous)
Dasatinib(Unsafe)
Rituximab(Low Risk)
Bevacizumab(Low Risk)
Thioguanine(Dangerous)
Vincristine(Dangerous)
Pazopanib(Unsafe)
Erlotinib(Unsafe)
Tamoxifen(Dangerous)
Nilotinib(Unsafe)
Mitoxantrone(Dangerous)
Imatinib(Unsafe)
Gemcitabine(Dangerous)
Dasatinib(Unsafe)
Orlistat(Low Risk)
Pazopanib(Unsafe)
Erlotinib(Unsafe)
Nilotinib(Unsafe)
Imatinib(Unsafe)
Dasatinib(Unsafe)
Pazopanib(Unsafe)
Erlotinib(Unsafe)
Nilotinib(Unsafe)
Imatinib(Unsafe)
Dasatinib(Unsafe)
Pazopanib(Unsafe)
Erlotinib(Unsafe)
Nilotinib(Unsafe)
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.